ClinicalTrials.gg
Not yet recruitingNCT07459595Updated Mar 10, 2026

Metformin Versus Myo-inositol in the Management of Polycystic Ovarian Disease: A Comparative Study

A Phase 1 interventional study of Myoinositol and Metformin in Polycystic Ovarian Syndrome (PCOS), sponsored by Fatima Tariq. Not yet recruiting at 1 site in Pakistan. Open to female participants aged 16 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Fatima Tariq · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
16 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies testing inositol in Polycystic Ovary Syndrome — 5 open to participants now, 6 under way, 1 of them phase 3. Inositol · Polycystic Ovary Syndrome.

Planned enrollment
18th of 32
60 · median 73
Started
2026
with 2 others
Phase 1
2 of 33
1 open now
Registered
28th of 33
by date
Lead sponsor
1 of 33
Fatima Tariq

Among the 33 studies testing inositol in Polycystic Ovary Syndrome, this one is the 18th largest by planned enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 1, and was the 28th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

5 of the 33 studies testing inositol in Polycystic Ovary Syndrome are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About inositol

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 16 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing inositol in Polycystic Ovary Syndrome, or all of them as a file.
02

Study summary

In polycystic ovary syndrome (PCOS), changes in physical appearance i.e. weight gain, hirsutism, menstrual disturbances and infertility result in reduced quality-of-life. PCOS is one of the most common endocrine disorders affecting about 4% to 8% of women of reproductive age. Diagnosis is primarily clinical with Rotterdam criteria being the most commonly followed criteria, which require the presence of two out of the three criteria including oligo and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries on ultrasound.

The objective of this study is to compare the outcome of Metformin versus Myo-inositol in the management of polycystic ovarian disease.

03

Conditions studied

  • Polycystic Ovarian Syndrome (PCOS)

Keywords

  • Metformin
  • Myo-inositol
  • Polycystic Ovarian Syndrome (PCOS)
04

Who can participate

Ages eligible
16 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Married or unmarried
  • Diagnosed with PCOS (females presenting with compliant of irregular cycle for >3 months, with hirsutism, acne, presence of polycystic ovaries detected on ultrasound ).

Exclusion criteria

Exclusion Criteria:

  • Females already taken or taking PCOS treatment (on medical record)
  • Females already enrolled in another trial program
  • Females already taking trial drugs
  • Females with chronic diabetes (BSR>200 mg/dl), hypertension (BP≥140/90mmHg)
  • Females with PCOS along with gestational sac (on ultrasound)
  • Females allergic to any content of trial drugs (on history)
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    In group A, females will be prescribed oral myoinositol 1g twice daily for 3 months

    Informed consent will be obtained from each female. Demographic data (name, age, height and weight for BMI, duration of symptoms (irregular cycles from how many months), marital status, parity, residence, socioeconomic status, diet pattern, family history of PCOS, and life style will be recorded. Females will be asked for their menstrual cycle duration and irregularity. Females will be prescribed oral myoinositol 1g twice daily for 3 months. All females will be followed-up in OPD for 3 months. After 3 months, females will be asked for their menstrual cycle duration and regularity. Reports will be assessed and levels will be recorded. If females will have regular cycles, then it will be noted. Females will be asked to give a blood sample on 3rd day of menstrual cycle and LH/FSH ratio will be noted. All this data will be recorded in a specially designed proforma

    Drug: Myoinositol

  • Active comparator
    In group B, females will be prescribed oral metformin 850 mg twice daily for 3 months

    Informed consent will be obtained from each female. Demographic data (name, age, height and weight for BMI, duration of symptoms (irregular cycles from how many months), marital status, parity, residence, socioeconomic status, diet pattern, family history of PCOS, and life style will be recorded. Females will be asked for their menstrual cycle duration and irregularity. Females will be prescribed oral sustained-release metformin 850 mg twice daily for 3 months. All females will be followed-up in OPD for 3 months. After 3 months, females will be asked for their menstrual cycle duration and regularity. Reports will be assessed and levels will be recorded. If females will have regular cycles, then it will be noted. Females will be asked to give a blood sample on 3rd day of menstrual cycle and LH/FSH ratio will be noted. All this data will be recorded in a specially designed proforma.

    Drug: Metformin

Interventions

  • DrugInositolStudies of InositolInositol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In group A, females will be prescribed oral myoinositol 1g twice daily for 3 months.

  • In group B, females will be prescribed oral sustained-release metformin 850 mg twice daily for 3 months.

06

What researchers measure

Primary outcomes

  1. LH/FSH ratio

    It will be assessed in terms of ratio between LH and FSH after 3 months of treatment.

    Time frame: 3 Months

  2. Regular cycles

    It will be labeled if number of days from the start (day 1) of one period until the start (day 1) of the next period are almost equal for at least 3 months

    Time frame: 3 Months

07

Study locations

1 site
  • CMH Gujranwala
    Guiranwala, Punjab Province 52230, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jul 2026, 2 months later.

Of 27 phase 1 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 147. This study's planned 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 10, 2026
StartEst.
May 1, 2026
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jul 31, 2026
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07459595
Lead sponsor
Fatima Tariq
Responsible party
Fatima Tariq (Principal Investigator, Combined Military Hospital Gujranwala) — Sponsor-investigator
First posted
Mar 10, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Mar 10, 2026

Study contacts

Dr Fatima Tariq, MBBS
Contact
ftmtariq@yahoo.com
+92315491846

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inositol

Start the discussion